Keith Ammon

relative to the taxation of farm and farm structures.

relative to environmental, social, and governance-related investment strategies by the state retirement system.

relative to rabies vaccines for animals.

relative to the offense of improper influence and making synthetic and semisynthetic kratom illegal to prepare, distribute, manufacture, sell, possess, or advertise, with exceptions made for scientific research.

relative to the right to compute.

relative to prescribing ibogaine for investigational use only and adopting the physician associate licensure compact.

requiring utilities and electric grid operators to assess and report the vulnerability of high-voltage transformers to geomagnetic and electromagnetic disturbances, and to recommend mitigation measures to protect the state electric infrastructure.

subjecting taxpayer funded investigations to the right-to-know law.

relative to the application of the Internal Revenue Code to provisions of the business profits tax.

relative to the penalty for false reports of suspected abuse and neglect made to the division for children, youth, and families, relative to owner's project manager services for school building aid projects, and relative to long-term care eligibility and making an appropriation therefor.

requiring municipalities, towns, and cities to submit documentation to the department of revenue administration proving they are in compliance with local budget and tax caps.

establishing a committee to study New Hampshire's electric renewable portfolio standard and the renewable energy fund.

relative to licensing requirements for health care facilities that operate on a membership-based business model.

relative to the classification and protection of personal digital information and cloud-stored files.

relative to eliminating the default budget from the official ballot referenda.

relative to the display of license plates on vehicles.

relative to the town meeting form of local governance.

relative to civil rights enforcement.

relative to consumer health care cost transparency.

relative to increasing transparency in the 340B Drug Pricing Program.